In this article
Juvenile laryngeal papilloma is more common in children and adolescents, and is mainly caused by mother-to-child transmission during delivery through the birth canal in cases where pregnant women carry low-risk HPV infections in the reproductive tract. The primary HPV types responsible are HPV 6 and 11. Children with juvenile laryngeal papilloma may show no clinical symptoms in the early stage, but as the papilloma grows, respiratory symptoms begin to appear. If the lesion becomes extensive, it can cause severe breathing difficulties and even death.
Screening pregnant women for cervical cancer to identify and address HPV infections can effectively prevent the virus from being transmitted to babies during childbirth. Cervical cancer screening for pregnant women or women of appropriate childbearing age is particularly important, as this group bears the health and happiness of two or even three generations. Since human intervention can now be used for disease prevention and medical technology has advanced so significantly, preventing disease before it happens has become a real and accessible goal for every woman.
Routine high-risk HPV typing and liquid-based cytology tests are recommended for women before pregnancy. If the test result is positive, colposcopy is recommended. If colposcopy identifies a suspicious lesion, a cervical biopsy is performed. If cervical cancer or precancerous lesions are found, it is advised to wait for the cervical lesions to heal before considering fertility.
For pregnant women who are found to carry low-risk HPV infections — particularly HPV types 6 and 11 — in the reproductive tract before or during pregnancy, delivery by caesarean section is recommended to minimize the risk of juvenile laryngeal papilloma in the newborn. Taking these screening and delivery steps seriously is one of the most meaningful ways women can protect both their own health and the health of their children.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Sai Sree
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.